Skip to main content
. Author manuscript; available in PMC: 2022 May 6.
Published in final edited form as: Leukemia. 2021 Nov 6;36(3):723–732. doi: 10.1038/s41375-021-01441-9

Figure 7. CLL Cells from Patients with Toxicity Show Increased Priming at Baseline, with a Decrease after 1 Week of Duvelisib.

Figure 7.

BH3 profiling on dFCR patients with (N=8) and without autoimmune toxicity (N=4), at baseline (A), and after 1 week of duvelisib therapy (B). BIM and PUMA BH3 peptides (x-axis) independently assess priming for apoptosis, and delta cytochrome C loss (y-axis) represents the degree of mitochondrial outer membrane permeabilization. * p<0.05; ** p<0.01.